Speaker:

So I'm going to invite Associate Professor Samir Viswanathan up to moderate

Speaker:

the panel discussion and our panellists, if you wouldn't mind taking a seat.

Speaker:

Thank you. And somehow.

Speaker:

And ladies and gents, as I mentioned at the beginning, you will be able to submit

Speaker:

questions via the Slido app using the QR code on your agenda if you'd like,

Speaker:

or Liesl and I will be walking around with the microphones as well.

Speaker:

So, to start off.

Speaker:

Thanks, Fred, Sam and Mustafa. So, we'll start off with the first question.

Speaker:

What percentage of those presenting in primary care with evidence of inflammatory

Speaker:

polyarthropathy have biological markers which assist in diagnosis?

Speaker:

I guess that's to you, Fred. Yeah, 70 to 80%.

Speaker:

So it's about 20% that have less than that in terms of trying to prove a diagnosis.

Speaker:

So it's not infrequent, but it is.

Speaker:

So if you're using blood testing, then you won't see much blood testing in psoriatic arthritis.

Speaker:

So that's the drama. But for rheumatoid, it's quite high, 70% to 80%.

Speaker:

For lupus, it's 99%. And for psoriatic arthritis, that's the harder bit because

Speaker:

you won't have blood test proof, but you'll have historical proof.

Speaker:

Fred can I ask a question on behalf of the orthopedic surgeons when do you stop,

Speaker:

you know DMARDs and biological agents before surgery and when do you restart?

Speaker:

Before surgery it's usually around the half life but for conventional synthetic

Speaker:

drugs so methotrexate luflunamide, plaquenil, hydroxychloroquine,

Speaker:

those drugs a week before is fine for biologic drugs it depends on the drug

Speaker:

but generally you'll go for, say, the drug lasts a month.

Speaker:

So for golimumab is a monthly injection, stop a month before.

Speaker:

For TNF blockade, some of them, again, it's another TNF blocking drug,

Speaker:

is a tanacep, that's a week.

Speaker:

So it depends on the drug, but generally it'll be the half-life of the drug.

Speaker:

And then starting after, because the complication rates from all of the surgery

Speaker:

you guys do is really quite low, like you don't get many. Thank you.

Speaker:

No, really. Like it's unbelievable what people do.

Speaker:

And so the surgical infection rate is so low that generally you can start a week later.

Speaker:

So once the surgeon says to me, you're fine, which is usually five,

Speaker:

seven days, you can just get started again.

Speaker:

Fantastic. Another question. What level of ANA is considered positive in SLE?

Speaker:

So it depends on the time of the, oh, sorry, the age of the patient.

Speaker:

So a baby, they shouldn't have a positive ANA. So as age increases,

Speaker:

the ANA frequency increases.

Speaker:

So it depends on that a little bit. But most of the time, like in a baby, it'll be one in 80.

Speaker:

But in an adult, say a middle-aged person, it'll be one in 640.

Speaker:

And then because lupus and other connective tissue diseases are like a jigsaw

Speaker:

puzzle, You want pieces of the puzzle to make the diagnosis.

Speaker:

You may accept a slightly lower ANA and then it sort of fits together.

Speaker:

So ANA on its own doesn't mean anything really.

Speaker:

It's all in association with the other symptoms.

Speaker:

Some connective tissue disease markers are more likely to be indicative of future

Speaker:

development of disease than others.

Speaker:

So an ANA on its own will not be a predictor of future disease,

Speaker:

but something like an anti-centromere antibody, that has a higher frequency

Speaker:

of developing into limited scleroderma, those sort of issues.

Speaker:

So it's a little bit contextual, but an ANA 1 in 640 would be reasonable to

Speaker:

consider that this is probably pathogenic in a person who has appropriate symptoms,

Speaker:

but heaps of people have blood tests with abnormalities, heaps,

Speaker:

without it being indicative of disease.

Speaker:

So the next question I I think all of us can answer. What is your analgesic

Speaker:

ladder for managing arthritis-related pain?

Speaker:

So, there are guidelines for this. So, I guess the gist of it is that you just

Speaker:

start off with the simple stuff first.

Speaker:

So, Panadol, Panadol, Osteo, and anti-inflammatory.

Speaker:

And then, if they don't work, then you sort of move up to, I guess,

Speaker:

the more, you know, the stronger stuff, the opioids.

Speaker:

If we're talking about sort of a chronic condition like arthritis,

Speaker:

someone's going to need to be on those for quite some time.

Speaker:

Generally speaking we should stay away from the longer

Speaker:

acting opioids i don't think they are

Speaker:

recommended anymore particularly for acute flare-ups or any sort of acute problem

Speaker:

including surgery i think there's been a strong move now to sort of like just

Speaker:

delete them completely from the management of at least acute pain but i would

Speaker:

argue also for chronic pain we should probably,

Speaker:

disencouraged the use of the, because they've just been associated with,

Speaker:

I guess, more of the problems of dependency and addiction and side effects, et cetera.

Speaker:

And the only other comment I make, sorry, I'm just hijacking this because it

Speaker:

is something that's close to my heart, is there seems to be this really negative

Speaker:

view of anti-inflammatories.

Speaker:

Every single patient that I come across.

Speaker:

And you say, oh, you should take an anti-inflammatory. And they go,

Speaker:

oh, no, no, no, I can't take an anti-inflammatory because it's going to kill my kidneys.

Speaker:

Or, you know, it's going to be so dangerous.

Speaker:

And I'm getting to the point now where I think this is some sort of like.

Speaker:

You know, marketing campaign by the opioid companies where they've got like,

Speaker:

they're just feeding all of this like false information to doctors and patients

Speaker:

about how terrible anti-inflammatories are.

Speaker:

And we know from studies that you can be on them for

Speaker:

like months and months and months and with very

Speaker:

little you know problem and the side effects are

Speaker:

very very rare and they do work right so

Speaker:

um and in some studies suggest that they work almost just as well as opioids

Speaker:

um in fact it's gotten to the point now where we're just about to do a randomized

Speaker:

trial where we're randomizing people to completely deleting the opioid medication,

Speaker:

so opioid sparing medication approach.

Speaker:

So it's going to be just Panadol and an anti-inflammatory versus something with

Speaker:

an opioid, a combination with opioids for people with acute fracture, right?

Speaker:

So you can imagine that that's a pretty significant presentation, right?

Speaker:

People leaving the hospital, recovering from their acute fracture.

Speaker:

We want to show or we want to see if people have as effective pain relief if

Speaker:

we just delete the opioids altogether.

Speaker:

Because every study that comes out, we're seeing more and more now that the

Speaker:

opioids are actually probably not as effective as what we thought they were.

Speaker:

Yeah. Do you remember the answer?

Speaker:

I generally add the COX-2, yeah. I'll just add to that.

Speaker:

I think if a patient is needing opiates for arthritis, I think that is a sign

Speaker:

that they're probably needing some sort of intervention.

Speaker:

I think my sort of general preference is getting them to Panadol,

Speaker:

Ostea regularly, Meloxicam or Ocelococcip regularly,

Speaker:

and then if that isn't helping injections, so getting them to have a corticosteroid

Speaker:

injection generally as a first line.

Speaker:

If they're a little bit reluctant, they can try the hyaluronic acid injection or the PRP.

Speaker:

But if they're starting to get onto the opiate treatment, I think that's the

Speaker:

point where they're probably not, I agree with Sam, I think dependence is an

Speaker:

issue And I think at that point, we should be considering surgical intervention.

Speaker:

Obviously, if it's very intermittent opiate use, then, you know,

Speaker:

they can probably have one end done in a blue moon.

Speaker:

But if they're needing end done every day, multiple times a day,

Speaker:

that's probably a sign that they should have surgical intervention if there

Speaker:

is a surgical option available for them. Just a quick question.

Speaker:

The question about, with a patient of mine who's on methotrexate,

Speaker:

doesn't want to go to the biologics, would we use plaquenil instead?

Speaker:

And also folinic acid, where does that come into?

Speaker:

So plaquenil is much safer, hydroxychloroquine is much safer than methotrexate.

Speaker:

Changing someone preoperatively to move on to something like hydroxychloroquine,

Speaker:

it doesn't work quickly enough.

Speaker:

And so we often won't switch but if we want

Speaker:

a lighter agent hydroxychloroquine's much better folinic

Speaker:

acid um i utilize that because a

Speaker:

bit of a hassle it's a bit more expensive so i utilize folinic acid when people

Speaker:

have intolerance to folic acid for whatever reason sometimes people feel a bit

Speaker:

funny about it um and also for hair loss sometimes people getting some hair

Speaker:

loss and i might give them folinic acid at that point um and it is much more

Speaker:

and is crucial in rescue therapy.

Speaker:

If someone overdoses on methotrexate, et cetera, then you can,

Speaker:

you generally use fulinc acid.

Speaker:

And I just wanted to follow up with the guys about what they commented around pain relief.

Speaker:

Completely appropriate. That's what the strategy should be to avoid narcotic analgesia.

Speaker:

And if you can think that anti-inflammatories are a disaster,

Speaker:

think about methotrexate. Every man and his dog is saying, don't do it.

Speaker:

And so it's quite problematic, but we get that a lot as well.

Speaker:

I can't use anti-inflammatories, but trying to avoid in longer term pain relief

Speaker:

for people who have problems from inflammatory disease and maybe secondary fibromyalgia

Speaker:

or other centralised pain syndromes,

Speaker:

I think getting the pain specialist involved is really quite useful.

Speaker:

And for joint areas, we might also involve them for blocks, et cetera.

Speaker:

So even sometimes people will have some pain post-operatively and they may benefit

Speaker:

from a geniculate nerve block, for example, in the knee.

Speaker:

And that can be done even if people have had some funny knee reaction after

Speaker:

a surgery where they've continued pain.

Speaker:

It doesn't work as well for preventing joint damage. So if you can get away

Speaker:

with hydroxychloroquine for reducing

Speaker:

cyanobitis and they don't have joint damage, then yes, it is better.

Speaker:

But the reason we start with methotrexate and rheumatoid is much more effective.

Speaker:

And time to, the earlier you treat and the faster the remission,

Speaker:

the lower your drug needs in the long term are.

Speaker:

So it's all about speed. A bit like cancer, hit hard, hit early,

Speaker:

fix, move on. And then you can reduce.

Speaker:

This one's for Mustafa. Can you please summarize the tibial and femoral osteotomy

Speaker:

for medial and lateral arthritis? Which one is which?

Speaker:

So for varus, if they're bow-legged,

Speaker:

generally the tibial-sided correction, so HTO for varus alignment,

Speaker:

and we make the patient valgus by about three to six degrees.

Speaker:

For valgus if

Speaker:

they're not neat we do a distal

Speaker:

femoral osteotomy and often you don't

Speaker:

do as much of an overcorrection so probably one

Speaker:

to two degrees of varus so varus

Speaker:

is hto and valgus is dfo which is distal femoral so um i'm not sure if that

Speaker:

uh is that that's great answer um steroid injection into the hip and if steroid

Speaker:

injection is given how soon can surgery be done sam,

Speaker:

Traversial. So, good question.

Speaker:

So, my personal view versus some of the maybe, you know, college statements that are coming out,

Speaker:

my personal view is it shouldn't be a hard and fast rule about restricting people

Speaker:

from having surgery after they've had an injection.

Speaker:

I think the evidence linking problems with people having injections to post-operative

Speaker:

complications is weak It is really sort of observational evidence when you think

Speaker:

about it People who are going to have more injections are probably more likely

Speaker:

to have more severe problems,

Speaker:

More reasons why they might be in pain.

Speaker:

The joint itself is probably in a worse state you can see why those people will

Speaker:

probably have a higher rate of complications.

Speaker:

There's a whole bunch of confounders here about why that person may have,

Speaker:

you know, a higher rate of post-op complications. It's not just the injection.

Speaker:

But on the other hand, restricting people from having surgery,

Speaker:

particularly if you work in a public system and,

Speaker:

you know, you're trying to get these people over the line and then their public

Speaker:

surgery, you know, date rocks up and they go, oh, no, no, no,

Speaker:

you can't have that surgery because you've just had an injection like a month

Speaker:

ago and then they have to go to the back of the list or delay them for another few months.

Speaker:

No, that's just bullshit, sorry, because that person really needs that surgery

Speaker:

because they're struggling, they need to have that treatment.

Speaker:

So for me, I'm much more circumspect about it, okay? I don't think there's a very strong link.

Speaker:

If someone has very mild symptoms and can be delayed, then yes,

Speaker:

you should probably delay a little bit.

Speaker:

In any case, you should probably just discuss it with the patient so that they're

Speaker:

aware, okay, that whole sort of shared decision-making model approach, right?

Speaker:

I've got two questions. One is the methotrexate. How long before you stop if

Speaker:

people want to fall pregnant and what do you substitute with?

Speaker:

So three months for pregnancy.

Speaker:

And so remember fathering children, you can just go through, it's not a big deal.

Speaker:

Three months and then substitution is with, depending on the illness,

Speaker:

but hydroxychloroquine is good in pregnancy.

Speaker:

Sulfosalazine is good in pregnancy. Biologics, TNF blockade is good in pregnancy

Speaker:

and some of the other biologics are likely to be also safe in pregnancy, but less clear.

Speaker:

And you can also use cyclosporine. So there are other agents that are safe in

Speaker:

pregnancy if people are flaring.

Speaker:

Other question is that you all say to put on people on anti-inflammatory,

Speaker:

but what happens with those people who are already on Noyak or Plavix?

Speaker:

Do they have an increased risk of bleeding?

Speaker:

They do have an increased risk of bleeding. And so anti-inflammatories do have

Speaker:

risks. So we can't pretend that they're perfectly safe, but they're pretty safe

Speaker:

because they're, you know, you can buy them over the counter.

Speaker:

And so we know that it's pretty safe and you can risk stratify.

Speaker:

So somebody who is taking other anticoagulant drugs, so if they're on apixaban

Speaker:

or eloquence, you shouldn't really do it because there is an increased rate

Speaker:

of bleeding in those situations, but you might factor in that and very occasionally.

Speaker:

If they're on warfarin, similarly. If they're taking other aspirin and Plavix

Speaker:

together, you're increasing the risk of bleeding, but you can mitigate that

Speaker:

a little bit with anti-ulcer drugs.

Speaker:

So it does come down to what person is, and that sort of person who's also on

Speaker:

an anticoagulant agent is likely to have ischemic heart disease,

Speaker:

is likely to have ulcer risk, is likely to have vascular problems and kidney disease.

Speaker:

They're not the right patient in general anyway, and that's what we're talking

Speaker:

about. well, we probably should think about surgical solutions to give them longer-term relief.

Speaker:

Or we say, look, anti-inflammatories may not be perfect, so we'd better get

Speaker:

your pain specialist help to try and work at other methods.

Speaker:

You mentioned in terms of autoimmune markers, and often they're positive,

Speaker:

but they don't have the clinical symptoms and they don't fit the diagnosis.

Speaker:

So what's your sort of, I guess, take on that in the sense that do you just

Speaker:

monitor these patients?

Speaker:

Should we be referring to a rheumatologist? We just monitor ourselves.

Speaker:

Yeah, look, it's complicated because I think you've got to use patient-reported outcomes.

Speaker:

So if somebody's really struggling and they can't do things,

Speaker:

we've got to think why aren't they able to do things? And then that person is

Speaker:

appropriate for referral.

Speaker:

So the other component is if they've

Speaker:

got some sort of organ system damage that's also causing a problem.

Speaker:

So being aware that maybe they're getting erosive disease and their blood tests

Speaker:

are not showing it and that's because they've got a spondyloarthritis.

Speaker:

Or I'll see people who are really functionally impaired, recurrent pericarditis.

Speaker:

Sometimes that will lead to constriction, but blood markers don't show anything.

Speaker:

And I think factoring out that blood is one metric, so blood is one thing.

Speaker:

Patients saying something is something.

Speaker:

Examination is something. The investigative tool that we show is also something.

Speaker:

And then not delineating and saying, well, because someone's complaining that

Speaker:

that isn't important. It is because they are also needing a solution.

Speaker:

So finding the appropriate solution, depending on the level of risk and harm, is probably the key.

Speaker:

But if somebody can manage, and they have no organ problem, so nothing that's

Speaker:

leading us to think they're going to have a significant issue,

Speaker:

then we can relax more and monitor.

Speaker:

But people feel very validated by hearing that you can understand that they're

Speaker:

struggling and we're recording this. And as they continue to record that problem, we may take more risk.

Speaker:

Yeah. And that's the problem. Because I guess there are a lot of people who

Speaker:

get these autoimmune screens done for various reasons.

Speaker:

Sometimes it's very vague complaints and you sort of do the autoimmune screen

Speaker:

thinking, oh, let's just exclude everything.

Speaker:

And then boom, the CCP is positive, but they don't have any clinical manifestations of RA.

Speaker:

So those people who then you say, hey, your CCP is positive,

Speaker:

obviously would get highly anxious but they don't have clinical symptoms of

Speaker:

rheumatoid, do you expect them

Speaker:

to then develop it over some period of time when it's highly specific?

Speaker:

Yes, so if you have a clinical syndrome that suggests that you have painful

Speaker:

joints to warrant the test for the CCP antibody.

Speaker:

And over the next two years, you are a 50% chance of developing rheumatoid with

Speaker:

a positive rheumatoid factor,

Speaker:

knowing that if you have a viral infection or some other problem,

Speaker:

you can develop a low-level CCP antibody.

Speaker:

But if you're doing the test, you're also doing it because they had something

Speaker:

that made you want to do it.

Speaker:

And so you can watch and see. But if they're continuing to have symptoms,

Speaker:

and if you did an MR or you did an ultrasound and you found inflammation,

Speaker:

then you can say maybe this person has an inflammatory syndrome.

Speaker:

So it's sort of checking more thoroughly and then saying, okay,

Speaker:

this CCP antibody is becoming more relevant. We can see it increasing now you've got symptoms.

Speaker:

Ladies and gents, we've just got time for one more question.

Speaker:

But the doctors will be here for the morning tea break, and you can introduce

Speaker:

yourselves to them and pick their brains. Thank you.

Speaker:

My question is about a steroid injection in the knee.

Speaker:

I've always been quite comfortable with hip, bursitis, shoulders,

Speaker:

but I go back to lecture after lecture when I was a young doctor where we were

Speaker:

told do not inject knees because of the risk of infection.

Speaker:

So I haven't ordered a steroid injection for a knee and I would like to know

Speaker:

when would I for pain, osteo or arthritis.

Speaker:

Sorry, I'd say the risk statistically is probably about one in 400.

Speaker:

So it is quite rare. It's definitely less risky than surgery.

Speaker:

So I think... When would you offer it to a patient? At what point?

Speaker:

So I think once they've exhausted the simple analgesics and before opiates,

Speaker:

I think it's safer than opiates as well. That's my opinion.

Speaker:

But I think if they've exhausted weight loss.

Speaker:

Low-impact exercise and panadol osteo and regular anti-inflammatory,

Speaker:

at that point, I think safer than all the other next-line options is a corticosteroid injection.

Speaker:

And often steroid injections do or don't work.

Speaker:

Is there any way of predicting the patient who might benefit better than another.

Speaker:

If you are, so there is some data suggesting that if you've got synovitis that's

Speaker:

present even in Norway, that you will do better from a steroid injection.

Speaker:

Doesn't mean they will, but they can often do better. And in the setting of

Speaker:

rheumatoid or lupus or those sort of things where you might have or psoriatic

Speaker:

arthritis and you might have an inflamed joint, steroid injection is actually really good.

Speaker:

And so you can do it in that situation quite comfortably and say,

Speaker:

I'm trying to avoid doing other stronger agents for you, particularly in psoriatic

Speaker:

arthritis, where you can go into remission.

Speaker:

And so you don't always need treatment for psoriatic arthritis because you can

Speaker:

have episodic disease. So I'm giving you this steroid injection to avoid something else.

Speaker:

And if you've got cyanovitis here and you've got OA, and I'm going to give you

Speaker:

an injection to try and do it, but the guys were presented that it gets less and less effective.

Speaker:

And so you might do it again and say, oh, it didn't work now.

Speaker:

Now we need to think of our other agents, but we got some time out of and the

Speaker:

data around repeated injections resulting in further OA is important to remember.

Speaker:

But these people are getting worse and need some help.

Speaker:

Nothing is risk-free. And so we've got to get people going.

Speaker:

They can't hear. We're always scared. Can I just add, just for your,

Speaker:

with cortisone injections, if the knee has a boggy swelling,

Speaker:

I think that's a good sign that it's sinovidic.

Speaker:

And a lot of GPs order an MRI straight away and often on the MRI report there'll

Speaker:

be a suggestion that the knee is synovitic and if it's synovitic cortisone injection

Speaker:

is not that bad it's a good idea for short term pain relief but it's not going to be a cure,

Speaker:

I probably wouldn't put one every six, I mean I'd limit it to one or two a year, perhaps three.

Speaker:

I don't know that there's a number about the total number of injections.

Speaker:

I know in the shoulder, the more injections you put in a shoulder,

Speaker:

the risk of developing a complication there is higher.

Speaker:

So if you correlate that to a knee, I'd say maybe limit it to one or two a year.